Eilean Therapeutics Advances FLT3 Inhibitor into Phase 1 Trials for Acute Myeloid Leukemia

Eilean Therapeutics LLC has announced FDA clearance of its Investigational New Drug (IND) application for lomonitinib, enabling Phase 1 clinical trials in the U.S. for relapsed/refractory acute myeloid leukemia (AML) with FLT3 mutations. Already underway in Australia, the U.S. trials will further explore lomonitinib's efficacy as a pan-FLT3/IRAK4 inhibitor, designed to combat common resistance mechanisms in AML treatment.

Eilean's CEO, Iain Dukes, highlights this approval as a testament to their innovative approach in drug development, conducted in collaboration with Expert Systems. The company remains committed to advancing its global clinical efforts to establish lomonitinib as a leading therapy in AML.